von Pawel, J., Spigel, D. R., Ervin, T., Losonczy, G., Barlesi, F., Juhász, E., . . . Reck, M. (2018). Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer. The oncologist (Dayton, Ohio), 23(6), 654-e58. https://doi.org/10.1634/theoncologist.2017-0690
Citácia podle Chicago (17th ed.)von Pawel, Joachim, et al. "Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer." The Oncologist (Dayton, Ohio) 23, no. 6 (2018): 654-e58. https://doi.org/10.1634/theoncologist.2017-0690.
Citácia podľa MLA (8th ed.)von Pawel, Joachim, et al. "Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer." The Oncologist (Dayton, Ohio), vol. 23, no. 6, 2018, pp. 654-e58, https://doi.org/10.1634/theoncologist.2017-0690.